"Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized,double-blind, placebo-controlled, clinical trial." by William McGee, MD

Article

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized,double-blind, placebo-controlled, clinical trial.

All Scholarly Works

William McGee, MD, Baystate Health

Link

Document Type

Article, Peer-reviewed

Publication Date

2-1-2004

Disciplines

Medicine and Health Sciences

Citation Information

Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized,double-blind, placebo-controlled, clinical trial. Crit Care Med 2004 Feb;32(2):332-41.